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Abstract
The prokaryote Mycoplasma pneumoniae is a major cause of respiratory disease in humans, accounting for 20% of all
community-acquired pneumonia and the leading cause of pneumonia in older children and young adults. The limitations of
existing options for mycoplasma diagnosis highlight a critical need for a new detection platform with high sensitivity,
specificity, and expediency. Here we evaluated silver nanorod arrays (NA) as a biosensing platform for detection and
differentiation of M. pneumoniae in culture and in spiked and true clinical throat swab samples by surface-enhanced Raman
spectroscopy (SERS). Three M. pneumoniae strains were reproducibly differentiated by NA-SERS with 95%–100% specificity
and 94–100% sensitivity, and with a lower detection limit exceeding standard PCR. Analysis of throat swab samples spiked
with M. pneumoniae yielded detection in a complex, clinically relevant background with .90% accuracy and high sensitivity.
In addition, NA-SERS correctly classified with .97% accuracy, ten true clinical throat swab samples previously established by
real-time PCR and culture to be positive or negative for M. pneumoniae. Our findings suggest that the unique biochemical
specificity of Raman spectroscopy, combined with reproducible spectral enhancement by silver NA, holds great promise as
a superior platform for rapid and sensitive detection and identification of M. pneumoniae, with potential for point-of-care
application.
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Introduction
Mycoplasmas are small, cell wall-less prokaryotes having a
minimal genome and limited biosynthetic capabilities that
necessitate a symbiotic lifestyle. Some species constitute part of
their host’s normal flora, but pathogenic mycoplasmas are
common and a significant threat to human and animal health.
Mycoplasma pneumoniae is a major cause of respiratory disease in
humans. Infections are acquired through respiratory secretions
and manifest in nonspecific upper respiratory tract symptoms
which may progress to tracheobronchitis and atypical broncho-
pneumonia. M. pneumoniae accounts for 20% of all community-
acquired pneumonia and is the leading cause of pneumonia in
older children and young adults [1]. However, the complexity of
M. pneumoniae pathogenesis, which can include extrapulmonary
spread, chronic sequelae such as asthma and COPD, and the
potential for secondary infection, complicates diagnostic strategies.
Serologic testing has long been the foundation for diagnosis of
M. pneumoniae infections, due to the considerable challenges posed
by direct culture [2,3]. Enzyme-linked immunoassay is the most
widely used commercially available serologic test for M. pneumoniae
in the U.S. and under ideal circumstances can yield comparable
sensitivity to PCR [4]. However, this requires sufficient time
following infection for an antibody response to develop and the
availability of paired acute- and convalescent-phase sera, thereby
limiting its value, particularly for point-of-care testing. PCR can
exhibit high sensitivity and yield positive detection sooner than
serological testing but is limited by issues of reliability, standard-
ization, and cost [1,5]. The inability to provide rapid and
definitive diagnosis of M. pneumoniae infections delays initiation of
appropriate treatment, prolongs morbidity, and increases the
likelihood of continued transmission and long-term sequelae,
highlighting the critical need for a new diagnostic platform with
high sensitivity, specificity, and expediency.
The unique biochemical specificity inherent to vibrational
spectroscopy has led to its evaluation for detection and
identification of infectious agents. Raman spectroscopy has several
features appropriate for biological samples, including narrow
bandwidths, good spatial resolution, and applicability to aqueous
samples, but the inherently low scattering cross-section of standard
Raman spectra has prevented its more widespread application for
biosensing purposes. The enhancement of the Raman spectrum of
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13633an analyte in proximity to metal surfaces (surface-enhanced
Raman spectroscopy, or SERS) can significantly increase spectral
intensity without loss of specificity, and consequently molecular
fingerprinting based on SERS has been applied to microorganisms
with considerable success [6–8]. However, realization of the
potential of SERS for biosensing applications has been limited by
inconsistency in the reproducibility and preparation of SERS-
active metal substrates, requiring optimized nanofabrication
strategies. To this end we have shown that oblique angle vapor
deposition can reproducibly yield aligned high aspect ratio silver
nanorod array (NA) substrates that generate SERS enhancement
factors of .10
8 and ,15% batch variation [9]. A second critical
element in the use of vibrational spectroscopy as a diagnostic tool
is the use of algorithms for specialized feature selection, rather
than examination of individual peaks. Chemometric analysis
reduces the dimensionality of the dataset, maximizes the variance
among spectral fingerprints, and provides a measure of the
reproducibility and sensitivity of the spectroscopic method. The
silver NA-SERS platform described here was previously shown to
exhibit outstanding sensitivity and specificity for detection and
differentiation of closely related strains of respiratory syncytial
virus and rotavirus, even in biochemically complex backgrounds
[10,11]. In the current study we demonstrated the capacity of this
biosensing platform to detect and distinguish with exceptional
sensitivity, both closely and more distantly related M. pneumoniae
strains in culture, and to detect M. pneumoniae in simulated throat
swab samples, representing a biochemically complex and clinically
relevant background. Furthermore, we analyzed ten true clinical
throat swab samples previously determined to be positive or
negative for M. pneumoniae by both real-time PCR and culture,
correctly classifying these spectra by NA-SERS with .97%
accuracy, and providing an indication of the potential this
technology may have for clinical application.
Methods
Mycoplasma strains and sample preparation
Wild-type M. pneumoniae strains M129 and FH were used in this
study, representing two major M. pneumoniae subtypes which shift in
dominance over a 4–7-year periodicity [12,13]. Despite reports of
new subtypes, there is good support for examination of these two
populations [13,14]. We also included strain II-3, a spontaneously-
arising avirulent mutant derived from M129 [15,16]. Mycoplas-
mas were cultured in SP4 medium [17] in tissue culture flasks at
37uC and harvested when the phenol red pH indicator was orange
(pH approx. 6.5), indicating log phase growth. For strains M129
and FH the spent growth medium was decanted and cells collected
by scraping in HPLC grade water, centrifuged, and washed 3X.
For strain II-3, which fails to attach to plastic (15), cell suspensions
were collected by centrifugation and likewise washed 3X. Washed
mycoplasmas were suspended in 500 ml water, syringe-passaged
10x with a 25-gauge needle, and aliquots of each were serially
diluted in water and plated on PPLO agar [18] for colony-forming
unit (CFU) determination. Water rather than buffered saline was
used initially to avoid possible damage to the silver nanorods by
chloride ions, and therefore parallel samples were also processed in
10 mM phosphate-buffered saline (PBS, pH 7.2) to assess loss of
viability in water. Mycoplasmas were fixed in 4% formalin for 3 h
and inactivation confirmed by 3-wk incubation in SP4 medium at
37uC with no change in the phenol red indicator. In subsequent
studies samples harvested in PBS or SP4 medium and formalin-
fixed before dilution with water exhibited no loss of NA-SERS
sensitivity or specificity or evidence of damage to the NA (data not
shown).
Throat swabs were collected from two of us, for which
Institutional Review Board (IRB) approval was not sought, as
the procedure was non-invasive, there were no risks involved, no
identifiers were included on the samples, and no additional
participants were recruited. The University of Georgia IRB
reviewed and approved the studies using banked true clinical
samples. For simulated infection studies, samples were collected
using sterile, polyester-tipped swabs (Puritan Medical Products Co,
Guilford, ME) and extracted with 1 ml HPLC grade water by
swirling and expressing against the side of the tube, syringe-
passaged for cell dispersion, and aliquoted for further processing.
Cultures of each in SP4 were negative for M. pneumoniae growth
after 6-wk incubation. Some aliquots were subsequently spiked
with serial 10-fold dilutions of fresh M. pneumoniae culture in water,
and each sample was fixed with 4% formalin. For analysis of true
clinical samples we used pre-existing banked throat swab samples
previously collected at the University of Alabama at Birmingham
(UAB) using UAB IRB-approved protocols. Samples were
extracted in SP4 medium containing polymyxin B, ampicillin,
and nystatin (500 units/ml, 1 mg/ml, 50 units/ml, respectively),
tested by culture and by real-time PCR [19], and stored frozen at
280uC. For NA-SERS testing, 3-ml aliquots were removed and
diluted 1:100 in water, with 1-ml volumes analyzed by NA-SERS
in duplicate as described below.
NA-SERS measurements and chemometrics analysis
Silver NA substrates were prepared for reproducible enhance-
ment of the Raman signal as described [11,20,21]. Briefly, an
electron beam evaporation system deposited three sequential
layers: a 20-nm Ti film, a 500-nm Ag film, and an obliquely
angled Ag NA. We used individual 161 cm substrates or 163 inch
substrates with 40 3-mm diameter polydimethylsiloxane-formed
wells [22]. Average specifications for Ag nanorods for optimum
signal production were previously determined to be approximately
900-nm length, 90–100-nm diameter, 13 nanorods/mm
2 surface
density, and formed 71u with respect to the surface normal [21].
Surface-enhanced Raman spectra were acquired using a Renishaw
inVia Reflex multi-wavelength confocal imaging microscope
(Hoffman Estates, IL). A Leica apochromatic 56 objective (NA
0.12) illuminated a 1265 mm
2 area on the substrate, allowing
spatial averaging and minimizing the effect of potential random
hot spots. A 785-nm near-infrared diode laser (Renishaw)
operating at 5% power capacity (15 mW) provided the incoming
radiation, with spectra collected in 10-sec acquisitions. Sample
imaging was accomplished by line-focus optics (diffraction grating
of 1200 lines/mm). Mycoplasma samples in 1 ml volumes were
applied to nanorod array substrates, and spectra from up to 10
random locations on each were analyzed to assess spectral
variation within a single substrate and among different substrates.
Raman spectra between 400–1800 cm
21 were collected using
Renishaw WiRE2.0 software. Instrument settings were optimized
to maximize signal and minimize saturation or degradation of
samples by the laser. Sample dilution, particularly with throat
swab specimens, eliminated formation of a visible film on the
substrate, which can prevent direct contact by the analyte and
diminish sensitivity, as we have described previously [11].
Raman spectra were first averaged using GRAMS32/A1
spectral software package (Galactic Industries, Nashua, NH) to
assess signal-to-noise quality, and baseline-corrected using a
concave rubberband algorithm which performed 10 iterations on
64 points to aid in preliminary evaluation and peak assignment
(OPUS, Bruker Optics, Inc., Billerica, MA). Raw spectra were pre-
processed for chemometrics using the first derivative of each
spectrum and a nine-point, 2nd-order polynomial Savitsky-Golay
Mycoplasma Detection by SERS
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with Unscrambler (CAMO, Freiberg, Germany) or Matlab 7.8
(Natlick, MA) software to allow direct intensity comparison
between samples and between variables within a sample [24].
The unsupervised methods of principal component analysis (PCA)
and hierarchical cluster analysis (HCA) were used to explore
clustering of similar spectra using Unscrambler software [24,25].
The diagonal matrix (y-block) for partial least squares discrimina-
tory analysis (PLS-DA) was generated in Excel and imported into
PLS toolbox 4.0 (Eigenvector, Wenatchee, WA) operating in
Matlab [26]. Both x- and y- block data were mean-centered prior
to PLS-DA [27]. Model robustness was tested by cross-validation
(CV) with Venetian Blinds, which builds a classification model
based on 90% of the data, tests the remaining 10% against that
model, and repeats the process through ten iterations to assess its
predictive power.
PCR analysis
DNA from 200 ml of each serial dilution was processed with the
QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA) as
recommended, except that the final centrifugation of the eluate
(50 ml) was performed after a 5-min elution. PCR was carried out
with a 16S rRNA primer set specific for M. pneumoniae [28] using
the EasyStart
TM 100 PCR mix-in-a-tube kit (Molecular Bio-
Products, San Diego, CA). Briefly, 5 ml of DNA, 0.31 mM each
forward and reverse primer, water, and 1 ml TaqPol (Fischer
BioTech, Pittsburgh,PA) were combined to a final volume of
50 ml. Reactions were carried out using an Eppendorf Mastercy-
cler (Hamburg, Germany) with thermocycler settings of 94uC for
2 min for cycle 1; 40 cycles of denaturation and extension at 94uC
for 1 min, 55uC for 1 min, 72uC for 2 min for cycle 2; and hold
indefinitely at 4uC for cycle 3. 10-ml volumes were analyzed by
agarose gel electrophoresis and ethidium bromide staining for the
expected 277-bp product.
Results and Discussion
Differentiation of M. pneumoniae strains
We compared baseline-corrected raw spectra for M. pneumoniae
strains FH, M129, and II-3 to assess reproducibility, collecting five
spectra from three separate wells on a 40-well array or three
independently fabricated substrates (Figure 1A and data not
shown), for a total of 15 spectra per strain. Alignment of the
spectra established their similarity with respect to Raman band
location and intensity but also revealed variation with spot and
substrate. To improve resolution of overlapping bands and
eliminate artifacts potentially introduced by baseline correction
we also compared first derivative spectra of these samples
(Figure 1B and data not shown). Comparison of the averaged
spectra and first derivatives thereof for all three strains collected
from different substrates (Figures 2A and 2B, respectively)
established strain similarity in Raman band wave number and
intensity but also revealed consistent strain differences, most
notably bands at 1460, 852, and 785 cm
21, and the regions
between 1325–1375, 1230–1295, and 1125–1175 cm
21
(Figure 2B, boxes), underscoring the need for multivariate
statistical analysis for further differentiation. The background
spectrum for formalin was inconsequential.
PCA and HCA are unsupervised statistical methods for data
analysis and form classes in the context of total variance [29,30].
PCA reduces dataset dimensionality and facilitates establishing
patterns and grouping of similar spectra for classification. Though
limited by 2-D projection, PCA by design explains successively
smaller proportions of the variance, with the first few principal
components explaining the greatest percentage of total variance.
Comparison of processed spectra principal components 1 and 3
clearly differentiated the three strains (Figure 3A), where each data
point corresponds to a single SERS spectrum. HCA is considered
more robust in the generation of classes than PCA due to inclusion
of additional dimensions [25,31] and correctly grouped 86 of 90
samples, with only 4 spectra from II-3 improperly clustered with
FH (Figure 3B).
PLS-DA is a full-spectrum, multivariate, supervised method
whereby prior knowledge of the classes (i.e. mycoplasma strains) is
used to yield more robust discrimination [27,32], minimizing
variation within classes while emphasizing latent variables between
or among classes. PLS-DA was applied to establish the statistical
significance of differences between the SERS spectra of the
mycoplasma strains. PLS-DA generated a model from 90 spectra
(30 per strain; same spectra as in Figure 3) with four latent
variables accounting for 57% of the total variance, differentiating
the strains with 93–100% sensitivity and specificity (Table 1); a CV
error ,0.05 was considered statistically insignificant as a
diagnostic threshold [33,34].
Figure 1. Reproducibility of spectra. Raw spectra (A)o fM. pneumoniae strain FH collected from five random spots from three separate NA
substrate wells, baseline corrected and offset. (B) First derivative spectra for strain FH from Figure 1A.
doi:10.1371/journal.pone.0013633.g001
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described for M. pneumoniae strains M129 and FH [35–37], hence
the capacity of NA-SERS to distinguish these was not surprising
based on recent success using this platform to distinguish rotavirus
strains [11]. However, strain II-3 is derived from M129, with a
nucleotide deletion in MPN453 resulting in loss of adhesin protein
Figure 2. Differentiation of M. pneumoniae strains. (A) Average spectra (n=15) of M. pneumoniae strains with formalin background, baseline
corrected and offset; and (B) first derivative spectra from panel A demonstrating strong similarities but also clear differences (boxes) among the
strains.
doi:10.1371/journal.pone.0013633.g002
Figure 3. Principal Component and Hierarchal Cluster Analyses. Chemometric analysis was conducted on the spectral data from Figure 2.
(A) PC scores plot 1vs. 3 of M. pneumoniae strains FH, M129, and II-3, as indicated. 77% of the variance was captured in PC1 and 3% in PC3 to
distinguish the strains. (B) HCA of pre-processed spectra of M. pneumoniae strains FH (dashed lines), M129 (solid lines), and II-3 (bold lines). Four
spectra from strain II-3 were misclassified with FH (at left).
doi:10.1371/journal.pone.0013633.g003
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[15,38], and therefore the capacity to distinguish M129 from II-3
was unexpected and underscores the discriminatory power of this
technology. Protein P65 also differs between M129 and FH [36]
and may represent a common denominator in the distinct spectral
signatures of these strains.
Sensitivity and limits of detection
To assess NA-SERS sensitivity further we analyzed the spectra
from ten serial ten-fold dilutions (10
21 to 10
210) per strain by PLS-
DA in a single model (Table 2), detecting and differentiating the
three strains with .94% sensitivity and specificity, an outcome
especially meaningful given the range in bacterial loads likely in
clinical samples. Spectra from the serial dilutions of strain II-3
were also assessed by PLS regression analysis, revealing a
correlation between true mycoplasma concentration and that
predicted for cross-validated samples (Figure 4). This correlation
suggests that spectral intensity reflects concentration, although
signal quenching was apparent with the most concentrated
mycoplasma suspensions. High SERS enhancement is achieved
through the local electric field between nanorods and requires that
the sample penetrate within the array itself [39], likely accounting
for the quenching effect at high sample concentrations. A similar
linear relationship was observed in the quantitative detection of
rotavirus by NA-SERS [11]. Finally, M. pneumoniae strain II-3
spectra were correctly differentiated at dilutions as high as 10
29,
corresponding to a lower limit of detection of 0.02 CFU/sample
analyzed on the substrate; a comparable limit was observed with
strain M129 (data not shown). By comparison, standard PCR
performed on parallel samples yielded the expected 277-bp
product from primers specific for the M. pneumoniae 16S rRNA
gene through the 10
27 dilution (Figure 5), which corresponds to a
lower detection limit by standard PCR of 3.6 CFU/reaction, or
0.7 CFU analyzed on the gel, consistent with the range reported
for M. pneumoniae by diagnostic PCR [40]. It is difficult to
extrapolate these results to the single-cell level for mycoplasmas,
which tend to clump and for which CFU and plating efficiency are
poorly defined [3]. Furthermore, we also cannot rule out the
possibility that intact cells are not essential, and the ability to detect
M. pneumoniae spectra may fall below the single-cell level due to
recognition by SERS of cell components in cell lysates, as was
reported recently for mycobacteria [41].
Analysis of simulated and true clinical throat swab
samples
We evaluated NA-SERS for the detection of M. pneumoniae
M129 in simulated throat swab samples as an initial assessment of
Table 1. PLS-DA of NA-SERS specificity and sensitivity in
discriminating M. pneumoniae strains.
Modeled class
a II-3 FH M129
Sensitivity (CV
b) 0.933 1.000 1.000
Specificity (CV) 1.000 1.000 1.000
Class Error(CV) 0.03 0 0
RMSEC
c 0.066 0.087 0.043
aFour latent variables, accounting for 57% of the total variance, were used to
generate the model.
bCV, cross validation.
cRMSEC, root mean squared error in calibration.
doi:10.1371/journal.pone.0013633.t001
Table 2. PLS-DA of NA-SERS specificity and sensitivity in
discriminating three M. pneumoniae strains and two negative
controls (formalin and water).
Modeled
class
a formalin II-3 FH M129 water
Sensitivity (CV) 0.98 0.96 0.941 1.000 1.000
Specificity (CV) 0.981 0.955 0.955 0.987 1.000
Class error (CV) 0 0.04 0 0.006 0
RMSEC 0.08 0.15 0.17 0.06 0.05
aabbreviations the same as in Table 1; single model generated using 12 latent
variables accounting for 88% of the total variance for all serial dilutions of each
strain.
doi:10.1371/journal.pone.0013633.t002
Figure 4. PLS regression analysis of serial dilutions of M.
pneumoniae. Serial 10-fold dilutions of strain II-3 spanning 10 logs of
concentration were assessed by PLS regression for degree of linearity in
actual intensity of the measured spectra plotted against the predicted
intensity. Starting concentration, 1.8610
9 CFU/ml; R
2=0.810.
doi:10.1371/journal.pone.0013633.g004
Figure 5. PCR analysis of serial dilutions of M. pneumoniae
strain II-3. Dilutions 10
210 to 10
0 are indicated; std, DNA size standard
(350 kbp); +, positive control (277 kbp). Starting concentration,
1.8610
9 CFU/ml.
doi:10.1371/journal.pone.0013633.g005
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analyzed spectra collected from individual and pooled throat
swab samples spiked with M. pneumoniae against control throat
swab samples (ten replicates of 1 ml each). Difference spectra from
spiked,pooled throatswab samples(8.2610
4 and 8.2610
3 CFU/ml)
after subtraction of the spectrum from the corresponding unspiked
pooled throat swab sample (Figure 6), provided an indication of
the contribution of M. pneumoniae to the spectral fingerprints
of each sample. For comparison, the average spectrum of M.
pneumoniae M129 is overlaid, revealing similar Raman band
positions and intensities with the difference spectra. Particularly
well aligned and correlating with the presence of M. pneumoniae
were peaks at 1598, 1459, 1367, 1332, 1241, 1031, 1004, 882,
619 and 525 cm
21 (Figure 6), and for most their intensity
correlated with M. pneumoniae CFU in the spiked samples (Figure 6
and data not shown). These bands have been characterized
previously in bacterial samples [42–44], with peak alignment at
1598 cm
21 associated with a C=C lipid; at 1459 cm
21 with
protein; at 1331 cm
21 with the C–H bend from protein; at
1241 cm
21 a well-established amide III band; at 1004 cm
21
characteristic of aromatic breathing modes in phe or tyr; at
882 cm
21 characteristic of C-C; and at 525 cm
21 attributed to
C-S-S-C bonds characteristic of cys and sulfated sugars. The
slight shifts in several of the bands can be explained by a
matrix effect, i.e. vibrational contributions of each background.
However, we are primarily interested in the entire spectral
fingerprint for potential diagnostic applications and therefore
used the multivariate PLS-DA to evaluate further the overall
spectral signatures for each dilution. A model built with all
dilutions and classification as positive or negative for M.
pneumoniae indicated .90% accuracy in cross-validated analysis
(Figure 7 and Table 3). The CV accuracy ranged from 0 to 0.105
when analyzed by individual dilution factor, while the full dataset
of all dilutions yielded a CV error of 0.033, corresponding to
98.1% specificity and 95.2% sensitivity for mycoplasma detection
in this biochemically complex, clinically relevant background.
Similar results were obtained when throat swab samples were not
pooled prior to spiking (data not shown). The lower detection
limit here of 82 CFU is comparable to that reported for real-time
PCR analysis of actual and spiked clinical samples [45] but may
underestimate the true limits of detection for throat swab
samples, as higher dilutions were not examined. Finally, as an
initial assessment of the potential of NA-SERS for detection of M.
pneumoniae in true clinical throat swab samples, we tested ten
specimens (five of each) previously shown to be positive or
Figure 6. Differentiation of spiked and control throat swab samples. Representative difference spectra of spiked, pooled throat swab
samples after subtraction of the spectrum of the un-spiked, pooled throat swab control. Bold and thin solid lines, spiked samples (8.2610
4 and
8.2610
3 CFU M. pneumoniae M129/ml, respectively); dashed line, representative spectrum of M. pneumoniae M129.
doi:10.1371/journal.pone.0013633.g006
Figure 7. PLS-DA of pooled throat swabs spiked with known
concentrations of M. pneumoniae strain M129. Open circles,
uninfected pooled throat swab samples; solid triangles, spiked throat
swab samples with 8.2610
4 CFU/ml; asterisks, spiked throat swab
samples with 8.2610
3 CFU/ml; squares, spiked throat swab samples with
8.2610
2 CFU/ml; open triangles, spiked throat swab samples with
8.2610
1 CFU/ml. A downward trend across the spiked samples toward
the threshold (dotted line) suggests that the model makes more errors
in classification with the higher dilution factors.
doi:10.1371/journal.pone.0013633.g007
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were collected for each sample, in duplicate, with PLS-DA
correctly classifying the spectra for all ten specimens as positive or
negative for M. pneumoniae with .97% accuracy (Figure 8 and
data not shown).
Conclusions
M. pneumoniae is a significant human respiratory tract pathogen
with respect to both incidence and impact, but diagnostic
strategies are complicated by symptoms that are typically
nondescript, a complex disease presentation that can include
extra-pulmonary sequelae, and multiple challenges posed by direct
culture. Serologic testing is the current method of choice for
diagnosis but suffers from severe limitations which make it
impractical and unreliable, while PCR can exhibit high sensitivity
but is prone to false negatives. Thus, the lack of an adequate
diagnostic platform for rapid detection with high sensitivity,
specificity, and expediency is a critical barrier to improved control
of M. pneumoniae infections.
The development of novel biosensors is yielding promising new
direct approaches for rapid and sensitive detection of infectious
agents. We previously established that this silver NA-SERS
platform exhibits robust and reproducible spectrum enhancement
for biosensing applications for viruses in pure preparations and in
cell lysates [10,11]. Here we extended those findings to bacteria
with a first assessment of detection of M. pneumoniae in culture, in
spiked throat swabs, and in true clinical samples. The platform
described here detected and differentiated three M. pneumoniae
strains in culture with excellent specificity and sensitivity and a
sub-CFU lower limit of detection. Furthermore, a lower limit of
detection at least as low as 82 CFU per sample was observed with
spiked throat swab samples, where a loss of sensitivity was
anticipated given the increased background complexity, as
previously observed with rotavirus detection by NA-SERS in cell
lysates [11].
Several potential challenges exist to widespread clinical
application of NA-SERS for mycoplasma detection. For example,
the increased biochemical complexity and variability in clinical
specimens could confound interpretation of the spectral patterns.
A recent study with clinical isolates of M. pneumoniae concluded
that standard Raman spectra (without surface enhancement) were
not informative for diagnostic differentiation of virulent and
avirulent strains [46]. However, a different study reports that
SERS spectra of bacteria are less congested and exhibit greater
species differentiation than their non-SERS counterparts [47].
This point is underscored by our findings that this NA-SERS
platform can detect and distinguish viruses in cell lysates with
high sensitivity [11] and differentiate M. pneumoniae at the strain
level (this study). A comprehensive analysis of diverse M.
pneumoniae clinical isolates is underway to assess further the
discriminatory capacity of NA-SERS. It will also be necessary to
expand the testing of spiked samples to include a broader
population as background controls and to assess detection in
alternative clinical samples such as throat washes, nasopharyngeal
swabs, and sputa. Moreover, variability in normal flora, including
other mycoplasma species, and in some cases the potential
presence of secondary agents, will complicate spectral analysis
and must be negotiated in discriminating an M. pneumoniae
spectral signature. It is also recognized that simulated throat swab
samples may not model true clinical samples accurately. In
particular, the background will likely reflect upper respiratory
tract inflammation in true clinical samples, while the interplay
between mycoplasma and host may differ with respect to
colonization parameters. However, our data with true M.
pneumoniae-positive and –negative clinical samples reveal compa-
rable sensitivity and specificity to results with simulated infection
(Figure 8). Finally, the potential impact of over-fitting a statistical
model must be considered, although the use here of independent
validation to assess the prediction capacity of our model yielded
promising results (data not shown). Nevertheless, taken together,
our experimental findings demonstrate the potential of this NA-
SERS diagnostic platform for expedient detection and identifi-
cation of M. pneumoniae in clinical samples with high sensitivity
and specificity.
Figure 8. PLS-DA of true clinical throat swab samples from
different individuals. Gray symbols, samples previously shown to be
M. pneumoniae-negative (Mp-negative) by culture and real-time PCR
from five persons; open symbols, samples previously shown to be M.
pneumoniae-positive (Mp-positive) by culture and real-time PCR from
five persons. Five or six spectra were collected for each sample, in
duplicate.
doi:10.1371/journal.pone.0013633.g008
Table 3. PLS-DA of throat swabs spiked with serial dilutions of M. pneumoniae.
Dilution (CFU/sample) Captured variance (x/y) RMSECV CV error
a Sensitivity Specificity
10
0 (8.2610
4) 36/94 .103 0 1.000 1.000
10
21 (8.2610
3) 72/93 .166 0 1.000 1.000
10
22 (8.2610
2) 71/79 .244 .0206 .968 .991
10
23 (8.2610
1) 66/58 .329 .105 .906 .882
All dilutions 75/83 .252 .033 .952 .981
aabbreviations same as in Table 1.
doi:10.1371/journal.pone.0013633.t003
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